<DOC>
	<DOCNO>NCT00740519</DOCNO>
	<brief_summary>This study conduct Europe . The main objective study assess safety self-titration type 2 diabetic patient antidiabetic tablet receive insulin first time . The study also look blood glucose control , frequency dose adjustment , clinic visit , time spent training patient self-titrate . The objective diabetes management achieve blood glucose level close possible normal order avoid late stage diabetic complication . Self-titration ( patient adjust insulin dosage ) offer potential well blood glucose control titration clinic visit . In recent year treatment type 2 diabetes United Kingdom move hospital GP surgery local clinic . Patients type 2 diabetes , general , train self-titration degree patient type 1 diabetes . Less experience self-titration could impact level blood glucose control outcome patient . Data study pool data NN304-3714 ( NCT00825643 ) report final study report NN304-3714 .</brief_summary>
	<brief_title>Observational Study Safety Self-titration Once Daily Levemir®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>After participate physician/nurse 's decision make initiate daily Levemir® therapy ( within license product ) , patient type 2 diabetes 18 year older currently treat diet , exercise one OADs offer participate Patients unable give write informed consent Current treatment insulin Patient deem unable unwilling selftitrate Known suspect allergy study product relate product Pregnancy breastfeed intention become pregnant within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>